These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 12517278)

  • 21. Wrong-side/wrong-site, wrong-procedure, and wrong-patient adverse events: Are they preventable?
    Seiden SC; Barach P
    Arch Surg; 2006 Sep; 141(9):931-9. PubMed ID: 16983037
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Medical errors in surgery.
    Emmott D
    Bioethics Forum; 2001; 17(2):26-31. PubMed ID: 12166431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of pharmacoproteomics in the development of personalized medicine.
    Jain KK
    Pharmacogenomics; 2004 Apr; 5(3):331-6. PubMed ID: 15102547
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacogenomics in dermatology: from susceptibility genes to personalized therapy.
    Pincelli C; Pignatti M; Borroni RG
    Exp Dermatol; 2009 Apr; 18(4):337-49. PubMed ID: 19348000
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacogenomics of adverse drug reactions: practical applications and perspectives.
    Becquemont L
    Pharmacogenomics; 2009 Jun; 10(6):961-9. PubMed ID: 19530963
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Are residents' extended shifts associated with adverse events?
    Szklo-Coxe M
    PLoS Med; 2006 Dec; 3(12):e497. PubMed ID: 17194193
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advances in the Pharmacogenomics of Adverse Drug Reactions.
    Collins SL; Carr DF; Pirmohamed M
    Drug Saf; 2016 Jan; 39(1):15-27. PubMed ID: 26650062
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HLA: a pharmacogenomics success story.
    Becquemont L
    Pharmacogenomics; 2010 Mar; 11(3):277-81. PubMed ID: 20235781
    [No Abstract]   [Full Text] [Related]  

  • 29. Will pharmacogenomics guide clinical practice?
    Licinio J; Alvarado I; Wong ML
    Pharmacogenomics J; 2002; 2(2):71. PubMed ID: 12049176
    [No Abstract]   [Full Text] [Related]  

  • 30. Osteoporosis pharmacogenomics: recent insights and future perspectives.
    Ostanek B; Marc J
    Pharmacogenomics; 2013 Apr; 14(5):451-4. PubMed ID: 23556441
    [No Abstract]   [Full Text] [Related]  

  • 31. [Notifications of adverse events from Norwegian health trusts 2011–17].
    Lindekleiv H; Johannessen T; Bugge E
    Tidsskr Nor Laegeforen; 2019 May; 139(9):. PubMed ID: 31140262
    [No Abstract]   [Full Text] [Related]  

  • 32. Quality Focus: First, Do No Harm: Adverse Drug Events.
    Schroeder SD
    S D Med; 2016 Dec; 69(12):565. PubMed ID: 28810110
    [No Abstract]   [Full Text] [Related]  

  • 33. Advances in the pharmacogenomics of adverse drug reactions.
    Alvarado I; Wong ML; Licinio J
    Pharmacogenomics J; 2002; 2(5):273. PubMed ID: 12439730
    [No Abstract]   [Full Text] [Related]  

  • 34. Pharmacogenomics at the tipping point: challenges and opportunities.
    Roden DM; Tyndale RF
    Clin Pharmacol Ther; 2011 Mar; 89(3):323-7. PubMed ID: 21326256
    [No Abstract]   [Full Text] [Related]  

  • 35. Facilitating clinical implementation of pharmacogenomics.
    Mrazek DA; Lerman C
    JAMA; 2011 Jul; 306(3):304-5. PubMed ID: 21771991
    [No Abstract]   [Full Text] [Related]  

  • 36. Minimize risk and costly adverse events with data gathering, reporting program.
    Data Strateg Benchmarks; 1997 Sep; 1(3):44-8. PubMed ID: 10345880
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A new tool for evaluation of medication errors applied to pediatric hematology].
    Queuille E; Bleyzac N; Auray JP; Bertrand Y; Souillet G; Philippe N; Duru G; Aulagner G
    Therapie; 2001; 56(6):775-83. PubMed ID: 11878110
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacogenetics and pharmacogenomics: adverse drug reactions.
    Jorgensen A; Alfirevic A
    Pharmacogenomics; 2008 Oct; 9(10):1397-401. PubMed ID: 18855528
    [No Abstract]   [Full Text] [Related]  

  • 39. Pharmacogenomics of lipid-lowering therapies.
    Hu M; Tomlinson B
    Pharmacogenomics; 2013 Jun; 14(8):981-95. PubMed ID: 23746191
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacogenomics and active surveillance for serious adverse drug reactions in children.
    Loo TT; Ross CJ; Sistonen J; Visscher H; Madadi P; Koren G; Hayden MR; Carleton BC
    Pharmacogenomics; 2010 Sep; 11(9):1269-85. PubMed ID: 20860467
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.